|
|
![]() |
![]() ![]() |
![]() |
|
||
![]() |
![]() |
Re: ACAD review from Biopharma Acadia is now only 9.5% of my portfolio now. I keep a spreadsheet with a column that shows the percent of holdings for each stock. This gets updated automatically based on the stock prices. Lucky for me I stuck with keeping my Acadia investment to no more than 20% of my portfolio at the time of purchase. Of course, that number changes as my stocks go up and down. This is what saved me on Acadia. I also lucked out on ITCI. My average buy-in on that is $15.51. Even if you average in my ITCI gains, my total returns for Biotech over the years were below-par considering the risk. Here are my returns for me biotechs: NERV - 0% - I sold out at break-even after being up significantly. ITCI 193% (gain) ACAD -36% (loss) NERV - Breakeven My total gain from all three is only 29%. When considering the length of time I have held these investments it has been a return well below what the S&P has done over the same period of time. My only gain with ITCI was almost pure luck as they were not expected to get approval. Once I dump ITCI and ACAD I will likely keep my biotech stocks to a minimum in my portfolio. I am looking for an exit for both. |
![]() ![]() ![]() ![]() |
return to message board, top of board |